DIAMONDS OF THE GREEK ECONOMY 2016
In 1999, VIANEX acquired its fourth factory, considered one of the most sophisticated of the few cephalosporin manufacturing plants in Europe. In 2006, the company incorporated Eldrug, a company active in research and development, and in 2011 VIANEX was approved as a supplier by the World Health Organization and UNICEF. 2013 was another important year for the group, which, now led by Dimitris Giannakopoulos, signed an agreement with Eli Lilly for the annual production of 10,000,000 units of vancomycin, 100% of which is exported to China. In 2015, VIAN SA started marketing and distributing Depon, the best-selling analgesic-antipyretic products, following an agreement with Bristol-Myers Squibb. An important fact is the announcement of a new agreement with the pharmaceutical company, MSD, signed in early 2016, renewing, in the best manner possible, 33 years of successful cooperation. Today, VIANEX leads the Greek pharmaceutical industry, with a high-level production capacity and a workforce exceeding 1,100 employees. Its activities involve all aspects of pharmaceutical production and marketing, and it constantly upgrades the range of its services to the market. Despite the adverse economic conditions in recent years, Vianex has been pursuing new, major cooperation with international pharmaceutical companies, aiming to import innovative pharmaceutical products into the domestic market. Operating in a highly competitive environment, Vianex is well positioned to capitalise on opportunities, relying on its experience, know-how and its unique and specialised production capacity.
Vianex S.A. 2013 Turnover 247,498,029.00 € Profit Before Taxes 10,490,406.00 € Gross Profit 68,768,322.15 € Net worth 43,131,941.00 € Liabilities 102,485,154.00 €
2014 206,889,570.00 € 4,329,899.00 € 49,950,769.00 € 22,855,061.00 € 108,646,094.00 €
Change (%) -16,4 -58,7 -28,4 -47,0 6,0
Diamonds 309